NeonMind Biosciences Inc.
NeonMind Biosciences Inc.
The Issuer is engaged in preclinical research to develop potential clinical treatments and wellness products to address obesity and weight management conditions and to promote health and wellness. The Issuer operates three divisions: (i) a pharmaceutical division engaged in drug development of psychedelic compounds with two lead psilocybin-based drug candidates targeting obesity; and (ii) a medical services division focused on launching specialty mental health clinics that integrate psychedelic therapeutics into traditional psychotherapy settings.
NeonMind Biosciences Inc. (NEON)
SEDAR Information
Company Info
Capitalization
News Releases
Bulletins
2022-0416 – Consolidation - NeonMind Biosciences Inc. (NEON)
le 14 avril/April 2022
NeonMind Biosciences Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every four (4) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 32,144,140 common shares.
The name and symbol will not change.
Advertisement
Publicité